Jazz Pharmaceuticals Valuation
| JAZZ Stock | USD 125.10 5.86 4.91% |
At this time, the firm appears to be undervalued. Jazz Pharmaceuticals PLC retains a regular Real Value of $156.82 per share. The prevalent price of the firm is $125.1. Our model calculates the value of Jazz Pharmaceuticals PLC from evaluating the firm fundamentals such as Return On Equity of 0.12, current valuation of 10.79 B, and Return On Asset of 0.0462 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Jazz Pharmaceuticals' valuation include:
Price Book 1.7282 | Enterprise Value 10.8 B | Enterprise Value Ebitda 8.2595 | Price Sales 1.8054 | Forward PE 6.4475 |
Undervalued
Today
Please note that Jazz Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Jazz Pharmaceuticals PLC is based on 3 months time horizon. Increasing Jazz Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Jazz Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Jazz Stock. However, Jazz Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 125.1 | Real 156.82 | Target 201.06 | Hype 125.97 | Naive 119.82 |
The intrinsic value of Jazz Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Jazz Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Jazz Pharmaceuticals PLC helps investors to forecast how Jazz stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Jazz Pharmaceuticals more accurately as focusing exclusively on Jazz Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Jazz Pharmaceuticals' intrinsic value based on its ongoing forecasts of Jazz Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Jazz Pharmaceuticals' closest peers.
Jazz Pharmaceuticals Cash |
|
Jazz Valuation Trend
Analysing the historical paterns of Jazz Pharmaceuticals' enterprise value and its market capitalization is a good way to estimate and gauge the value of Jazz Pharmaceuticals PLC over time and is usually enough for investors to make rational market timing decisions.
Jazz Valuation Data Drivers
Jazz Revenue by Product
Jazz Pharmaceuticals Total Value Analysis
Jazz Pharmaceuticals PLC is currently forecasted to have valuation of 10.79 B with market capitalization of 7.21 B, debt of 5.79 B, and cash on hands of 899.36 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Jazz Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
10.79 B | 7.21 B | 5.79 B | 899.36 M |
Jazz Pharmaceuticals Investor Information
About 99.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.73. Some equities with similar Price to Book (P/B) outperform the market in the long run. Jazz Pharmaceuticals PLC has Price/Earnings To Growth (PEG) ratio of 0.88. The entity recorded earning per share (EPS) of 7.06. The firm had not issued any dividends in recent years. Based on the key indicators related to Jazz Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Jazz Pharmaceuticals PLC is performing exceptionally good at this time. It has a great probability to report excellent financial results in December.Jazz Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Jazz Pharmaceuticals has an asset utilization ratio of 33.65 percent. This suggests that the Company is making $0.34 for each dollar of assets. An increasing asset utilization means that Jazz Pharmaceuticals PLC is more efficient with each dollar of assets it utilizes for everyday operations.Jazz Pharmaceuticals Ownership Allocation
Jazz Pharmaceuticals PLC has a total of 60.45 Million outstanding shares. The majority of Jazz Pharmaceuticals PLC outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Jazz Pharmaceuticals to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Jazz Pharmaceuticals PLC. Please pay attention to any change in the institutional holdings of Jazz Pharmaceuticals PLC as this could imply that something significant has changed or is about to change at the company. Also note that almost one million thirty-nine thousand eight hundred nineteen invesors are currently shorting Jazz Pharmaceuticals expressing very little confidence in its future performance.Jazz Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 3.83 B. Net Income was 414.83 M with profit before overhead, payroll, taxes, and interest of 3.39 B.About Jazz Pharmaceuticals Valuation
Our relative valuation model uses a comparative analysis of Jazz Pharmaceuticals. We calculate exposure to Jazz Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Jazz Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 3.4 B | 3.6 B | |
| Pretax Profit Margin | 0.08 | 0.08 | |
| Operating Profit Margin | 0.15 | 0.16 | |
| Net Profit Margin | 0.11 | 0.11 | |
| Gross Profit Margin | 0.89 | 0.71 |
Jazz Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 72.1 M | |
| Quarterly Earnings Growth Y O Y | 0.597 | |
| Forward Price Earnings | 6.4475 |
Jazz Pharmaceuticals Current Valuation Indicators
Valuation refers to the process of determining the present value of Jazz Pharmaceuticals PLC and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Jazz we look at many different elements of the entity such as Jazz's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Jazz Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Jazz Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Jazz Pharmaceuticals' worth.Additional Tools for Jazz Stock Analysis
When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.